Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe

  • Mena, Marisa|||0000-0003-2163-892X
  • Frias-Gomez, Jon|||0000-0002-0366-676X
  • Taberna, Miren|||0000-0002-2446-186X
  • Quirós, Beatriz|||0000-0002-6187-3732
  • Marquez, Sandra
  • Clavero, Omar|||0000-0001-9721-6382
  • Baena, Antoni.|||0000-0001-9221-8784
  • Lloveras, Belen|||0000-0001-8659-5241
  • Alejo, María
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • García, Jacinto Montero
  • Mesia, Ricard|||0000-0002-3785-3563
  • Bermejo, Josep Oriol|||0000-0002-8581-9415
  • Bonfill Abella, Teresa|||0000-0003-2775-0293
  • Aguilà, Antón
  • Guix, Marta|||0000-0002-2143-0697
  • Hijano, Rafael|||0000-0001-6787-5440
  • Pavón, Miguel Ángel|||0000-0003-3677-5329
  • Torres, Montserrat A.
  • Tous, Sara|||0000-0002-5423-7092
  • Clèries, Ramon|||0000-0002-3637-4747
  • Alemany, Laia|||0000-0003-0945-6015
The incidence of human papillomavirus (HPV)-related oropharyngeal cancer is increasing in some regions. Nevertheless, the epidemiology of this disease has not been extensively investigated in southern Europe. We conducted a retrospective cohort study of patients diagnosed with primary oropharyngeal cancer from 1991 to 2016. Cancer tissues underwent histopathological evaluation, DNA quality control, HPV-DNA detection and p16 immunohistochemistry. Data were collected from medical records. Factors associated with HPV positivity and time trends were evaluated with multivariable Bayesian models. The adjusted prevalence of HPV-related cases in 864 patients with a valid HPV-DNA result was 9.7%, with HPV-DNA/p16 double positivity being considered. HPV-related oropharyngeal cancer was likely to occur in non-smokers and non-drinkers, to be located in the tonsil or diagnosed at advanced stages. Time-trend analysis showed an increasing risk of HPV-related oropharyngeal cancer in the most recent periods (5-year period increase of 30%). This increase was highest and with a clear increasing trend only in the most recent years (2012-2016). The prevalence of HPV-related oropharyngeal cancer started to sharply increase in the most recent years in our setting, as occurred two decades ago in areas where most oropharyngeal cancer cases are currently HPV-related. Our results provide a comprehensive assessment of the epidemiological landscape of HPV-related oropharyngeal cancer in a region of southern Europe.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The use of HPV16-E5, EGFR, and PEGFR as prognostic biomarkers for oropharyngeal cancer patients

  • Taberna, Miren|||0000-0002-2446-186X
  • Torres Tarrés, Montserrat
  • Alejo, María
  • Mena, Marisa|||0000-0003-2163-892X
  • Tous, Sara|||0000-0002-5423-7092
  • Marquez, Sandra
  • Pavón, Miquel A.
  • León, Xavier|||0000-0002-8393-2721
  • Garcia Lorenzo, J.|||0000-0002-6123-7808
  • Guix, Marta|||0000-0002-2143-0697
  • Hijano, Rafael|||0000-0001-6787-5440
  • Bonfill Abella, Teresa|||0000-0003-2775-0293
  • Aguilà, Antón
  • Lozano, Alicia|||0000-0003-0528-5212
  • Mesia, Ricard|||0000-0002-3785-3563
  • Alemany, Laia|||0000-0003-0945-6015
  • Bravo, Ignacio G.
Anti-epidermal-growth-factor-receptor (EGFR) therapies in combination with radiotherapy are being studied on deescalation clinical trials for HPV-related oropharyngeal cancer (OPC) patients. The HPV16-E5 oncoprotein increases recycling of activated EGFR to the cell surface, enhancing factor signal transduction. Our aim was to evaluate viral HPV16-E5 oncogene expression as well as EGFR and phosphorylated-EGFR (pEGFR), protein levels as biomarkers for clinical outcome in a retrospective cohort of OPC patients. Formalin-fixed-paraffin-embedded OPCs were collected from 1990 to 2013. OPC samples containing HPV-DNA were subject to viral E6*I mRNA detection and p16INK4a immunohistochemistry (IHC). HPV16-positive cases were evaluated for HPV16-E5 (RT-PCR) and EGFR/pEGFR (IHC). A stratified and matched random sample of HPV-negative samples was used as control and evaluated for EGFR/pEGFR. Overall survival (OS) and disease free survival (DFS) estimates were assessed for locally advanced OPC patients (stage III, IVa,b 7th edition). Among 788 OPC patient samples, 53 were double positive for HPV16-DNA/p16. HPV16-E5 expression was found in 41 of 53 samples (77.4%). EGFR expression was observed in 37.7 vs 70.8% of HPV16-positive vs HPV-negative samples, respectively; (adjusted OR = 0.15) 5% CI = 0.04-0.56]). Expression of pEGFR followed an inverse pattern with 39.6 and 24.9% detection in HPV16-positive and HPV-negative samples; (adjusted OR = 1.58 [95% CI = 0.48-5.17]). Within HPV16-positive cases, no association between HPV16-E5/EGFR nor pEGFR was observed. With a median follow-up of 39.36 months (min = 0.03 - max = 272.07), the combination of HPV status and EGFR or pEGFR expression were predictors of better OS (p < 0.001, for both) and DFS (p < 0.001 for EGFR and p = 0.003 for pEGFR). HPV16-E5 is highly expressed on HPV16-positive OPCs. Interestingly, HPV16-positive cases expressed significantly more pEGFR while HPV-negative cases expressed more EGFR. The combinations of HPV status and EGFR or pEGFR may be useful biomarkers for evaluating prognosis outcome in OPC patients.